Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report

Watanabe,Hiroko; Tamura,Tomohiro; Shiozawa,Toshihiro; Ohara,Gen; Kagohashi,Katsunori; Kawaguchi,Mio; Kurishima,Koichi; Satoh,Hiroaki; Hizawa,Nobuyuki

doi:10.3892/mco.2015.531

July-2015 Volume 3 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2015 Volume 3 Issue 4

Full Size Image

Case Report

Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report

Authors:
- Hiroko Watanabe
- Tomohiro Tamura
- Toshihiro Shiozawa
- Gen Ohara
- Katsunori Kagohashi
- Mio Kawaguchi
- Koichi Kurishima
- Hiroaki Satoh
- Nobuyuki Hizawa
View Affiliations / Copyright

Affiliations: Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310‑0015, Japan, Division of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan
Pages: 889-891
|
Published online on: March 30, 2015

https://doi.org/10.3892/mco.2015.531
Expand metrics +

Abstract

Therapy with crizotinib achieves prolonged progression-free and overall survival in non-small-cell lung cancer (NSCLC) patients with echinoderm microtubule‑associated protein‑like 4 (EML4)‑anaplastic lymphoma kinase (ALK). It was demonstrated that ALK‑positive NSCLCs exhibit a high response rate to the ALK inhibitor, crizotinib. However, a proportion of the patients discontinue crizotinib treatment due to adverse events. This is the case report of a NSCLC patient with EML4‑ALK rearrangement, who, following crizotinib discontinuation for one year due to adverse events, exhibited a marked response to alectinib. Even if the incidence is not high, clinicians should not overlook the most common crizotinib‑related adverse events. Furthermore, certain patients may continue to benefit from alectinib following long‑term discontinuation of crizotinib therapy.

View Figures

View References

1	Landi L and Cappuzzo F: Management of NSCLC: Focus on crizotinib. Expert Opin Pharmacother. 15:2587–2597. 2014. View Article : Google Scholar : PubMed/NCBI
2	Frampton JE: Crizotinib: A review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs. 73:2031–2051. 2013. View Article : Google Scholar : PubMed/NCBI
3	Rossi A, Maione P, Sacco PC, Sgambato A, Casaluce F, Ferrara ML, Palazzolo G, Ciardiello F and Gridelli C: ALK inhibitors and advanced non-small cell lung cancer (review). Int J Oncol. 45:499–508. 2014.PubMed/NCBI
4	Gadgeel SM, Gandhi L, Riely GJ, et al: Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 15:1119–1128. 2014. View Article : Google Scholar : PubMed/NCBI
5	Pikor LA, Ramnarine VR, Lam S and Lam WL: Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 82:179–189. 2013. View Article : Google Scholar : PubMed/NCBI
6	Kijima T, Takeuchi K, Tetsumoto S, et al: Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer. Cancer Sci. 102:1602–1604. 2011. View Article : Google Scholar : PubMed/NCBI
7	Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
8	Solomon BJ, Mok T, Kim DW, et al: PROFILE 1014 Investigators: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
9	Blackhall F, Kim DW, Besse B, et al: Patient-reported outcomes and quality of life in PROFILE 1007: A randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol. 9:1625–1633. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wu YL, Zhou C, Hu CP, et al: Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
11	Majem M and Pallarès C: An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: Focus on EGFR inhibitors and anti-angiogenic agents. Clin Transl Oncol. 15:343–357. 2013. View Article : Google Scholar : PubMed/NCBI
12	Köhler J and Schuler M: LUX-Lung 3: Redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer. Future Oncol. 10:533–540. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles